Answers are grounded in this paper and cite their sources.
Baseline TMTV is a strong independent predictor of outcome in FL. In combination with FLIPI2 score, it identifies patients at high risk of early progression. It warrants further validation as a biomarker for development of first-line PET-adapted approaches in FL.
No takes yet. Share an insight, caveat, or question.
Meignan et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: